C07C69/608

Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

This invention relates to methods for the synthesis of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

This invention relates to methods for the synthesis of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

Alkoxycarbonylation of trivinylcyclohexane

Process for the alkoxycarbonylation of trivinylcyclohexane.

Alkoxycarbonylation of trivinylcyclohexane

Process for the alkoxycarbonylation of trivinylcyclohexane.

Radiation-sensitive resin composition, method for forming resist pattern and compound

A radiation-sensitive resin composition includes a resin having a partial structure represented by formula (1). R.sup.1 and R.sup.2 each independently represent a substituted or unsubstituted chain aliphatic hydrocarbon group having 1 to 6 carbon atoms or a substituted or unsubstituted alicyclic hydrocarbon group having 3 to 6 carbon atoms, or R.sup.1 and R.sup.2 are bonded to each other to form a part of a 3- to 6-membered cyclic structure together with the carbon atom to which R.sup.1 and R.sup.2 are bonded; R.sup.3 represents a monovalent alicyclic hydrocarbon group having 4 to 20 carbon atoms and containing a fluorine atom. No fluorine atom is bonded to carbon atoms located at ?-, ?- and ?-positions of the carbon atom to which R.sup.1 and R.sup.2 are bonded; and No fluorine atom is bonded to carbon atoms located at ?- and ?-positions of the carbon atom to which R.sup.3 is bonded. ##STR00001##

Radiation-sensitive resin composition, method for forming resist pattern and compound

A radiation-sensitive resin composition includes a resin having a partial structure represented by formula (1). R.sup.1 and R.sup.2 each independently represent a substituted or unsubstituted chain aliphatic hydrocarbon group having 1 to 6 carbon atoms or a substituted or unsubstituted alicyclic hydrocarbon group having 3 to 6 carbon atoms, or R.sup.1 and R.sup.2 are bonded to each other to form a part of a 3- to 6-membered cyclic structure together with the carbon atom to which R.sup.1 and R.sup.2 are bonded; R.sup.3 represents a monovalent alicyclic hydrocarbon group having 4 to 20 carbon atoms and containing a fluorine atom. No fluorine atom is bonded to carbon atoms located at ?-, ?- and ?-positions of the carbon atom to which R.sup.1 and R.sup.2 are bonded; and No fluorine atom is bonded to carbon atoms located at ?- and ?-positions of the carbon atom to which R.sup.3 is bonded. ##STR00001##

2-(alkoxy or aryloxy carbonyl)-4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hex-2-enoic acid compounds, its preparation and use

Compounds of the formula 1 ##STR00001##
wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2 ##STR00002##

2-(alkoxy or aryloxy carbonyl)-4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hex-2-enoic acid compounds, its preparation and use

Compounds of the formula 1 ##STR00001##
wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2 ##STR00002##

PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS

Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer:

##STR00001##

wherein

##STR00002##

R.sub.2, R.sub.3 and R.sub.4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.

PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS

Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer:

##STR00001##

wherein

##STR00002##

R.sub.2, R.sub.3 and R.sub.4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.